Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cell Stem Cell|May 8, 2026
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AMLAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.
Cell Stem Cell|April 25, 2023
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemiaSergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, et al.
Nature Medicine|July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agentJulian Zoller, Michael Kalz, Xuewei Wu, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registryMaher Hanoun, Leo Ruhnke, Michael Kramer, et al.
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Molecular Therapy. Oncology|February 20, 2026
A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based constructAlexandros Kourtesakis, Hiu Nam Hannah Chow, Eileen Bailey, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Blood|July 20, 2022
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Christina Schmidt, Peter-Martin Bruch, et al.
Journal of Hematology & Oncology|July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trialMaria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Pageof 8